Elm Advisors’s Genomic Health, Inc. GHDX Stock Holding History

Elm Advisors’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$70K	–	287
2018 Q3	$70K	Buy	+1,000	New	+$58.5K	0.05%	137

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Elm Advisors's GHDX Position: Q4 2018 in Review

Elm Advisors sold out of Genomic Health, Inc. (GHDX) in Q4 2018, closing a stake of 1,000 shares — an estimated $70K sold.

Elm Advisors first reported a position in GHDX in Q3 2018 and held it in 1 quarter. The position peaked at $70K in Q3 2018. 228 funds tracked by Wall St. Rank hold GHDX as of Q4 2018.

Elm Advisors reported no remaining Genomic Health, Inc. position as of Q4 2018 after selling out during the quarter.
Elm Advisors sold 1,000 Genomic Health, Inc. shares in Q4 2018, an estimated $70K.
Elm Advisors first reported a position in Genomic Health, Inc. in Q3 2018 and held it in 1 quarter.
Elm Advisors's Genomic Health, Inc. position peaked at $70K in Q3 2018.
228 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2018.

Based on Elm Advisors's 13F filing for Q4 2018, filed 8 Jan 2019.